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Abstract: With continual rapid developments in the biomedical ﬁeld and understanding of
the important mechanisms and pharmacokinetics of biological molecules, controlled drug
delivery systems (CDDSs) have been at the forefront over conventional drug delivery
systems. Over the past several years, scientists have placed boundless energy and time into
exploiting a wide variety of excipients, particularly diverse polymers, both natural and
synthetic. More recently, the development of nano polymer blends has achieved noteworthy
attention due to their amazing properties, such as biocompatibility, biodegradability and more
importantly, their pivotal role in controlled and sustained drug release in vitro and in vivo.
These compounds come with a number of effective beneﬁts for improving problems of
targeted or controlled drug and gene delivery systems; thus, they have been extensively used
in medical and pharmaceutical applications. Additionally, they are quite attractive for wound
dressings, textiles, tissue engineering, and biomedical prostheses. In this sense, some important and workable natural polymers (namely, chitosan (CS), starch and cellulose) and some
applicable synthetic ones (such as poly-lactic-co-glycolic acid (PLGA), poly(lactic acid)
(PLA) and poly-glycolic acid (PGA)) have played an indispensable role over the last two
decades for their therapeutic effects owing to their appealing and renewable biological
properties. According to our data, this is the ﬁrst review article highlighting CDDSs
composed of diverse natural and synthetic nano biopolymers, blended for biological purposes, mostly over the past ﬁve years; other reviews have just brieﬂy mentioned the use of
such blended polymers. We, additionally, try to make comparisons between various nano
blending systems in terms of improved sustained and controlled drug release behavior.
Keywords: polymer blends, drug delivery, wound dressing, PLGA, chitosan, starch

Introduction
The past two decades have seen widespread progress in the development of drug
delivery vehicles. However, over the past several years, despite the signiﬁcant
advances in developing novel excipients for releasing speciﬁc drugs in a sustainable
and controllable way, limitations on experimental achievements have remained a
major concern. Thus, there is an urgent need for proposing new drug delivery
approaches to ameliorate this pressing issue.
Drug delivery systems (DDSs) consisting of biocompatible and biodegradable
materials that take into account distinct physiological and physiochemical changes,
are of special interest because they can signiﬁcantly release biological agents at the
right place and/or at a rate adjusted to disease progression.1 DDSs can be categorized
either as diffusion-controlled, chemically-controlled, swelling-controlled or modulated-release systems.2 Novel DDSs which release drugs at a controlled rate, slowly,
International Journal of Nanomedicine 2020:15 4363–4392
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and in a targeted manner have been promising.3 For more
than ten years, numerous articles of various concentrated
topics have been devoted to the ﬁeld of DDSs and several
advancements have been made. Nevertheless, it should be
kept in mind that many therapeutic agents may cause severe
side effects as they need to be delivered at a prolonged
exposure time which results in reducing their toxicity by
releasing smaller concentrations over longer drug exposure,
particularly, as antitumor and antibacterial agents.4,5

Polymers in Controlled Nano Drug
Delivery Systems
Controlled drug delivery systems (CDDSs) bring about a
variety of positive points, including improved drug administration, efﬁcacy and patient compliance, tailored therapeutic activity, reduced side effects, toxicity and drug
administration frequency, as well as improved premature
degradation.1,6,7 In all circumstances, the main purpose of
CDDSs is a sensible combination between biocompatible,
soft and biodegradable polymers and drugs such that drugs
can be released in a sustained or controlled manner over a
long time span (Figure 1).8 In order to acquire novel and
beneﬁcial controlled drug release, different approaches
among polymers have emerged—such as injectable
hydrogels,9 direct implantation,10 crosslinked micelles,11
injectable suspension12 and depots.13
As time goes by, biopolymers of various nanometer sizes,
shapes, and surface properties have played a crucial role as

CDDSs14 and their synergic effects have ameliorated drug
entrapment and mechanical property concerns.15 It is an indisputable fact that polymers—either natural or synthetic—have
become predominantly important materials as CDDSs, providing the weight, consistency and volume for the beneﬁcial
administration of drugs.16 Stimuli-responsive polymers could
mitigate the many dilemmas with biological systems, demonstrating a signiﬁcant response to modiﬁcations in chemical and
physical stimuli such as pH, temperature, concentration, pressure, ionic strength, light and redox potential.17 Hence, these
responses can lead to swelling, precipitation and dissolution,
along with a change in hydrophilicity and hydrophobicity.18
As our body is inﬂuenced by external stimuli by adjusting to
changing external conditions, rationally designed new responsive polymers are of particular importance to meet such criteria. For CDDs applications, devices must be able to deliver
agents at the right place in response to a stimulus and be easily
administered aside from possessing non-toxic, biocompatible
and biodegradable materials.19 Here, we attempt to include the
most recent publications of stimuli-responsive polymers in
CDDSs by introducing one of the most notable types of
these materials used for CDDSs, namely crosslinked polymer
networks termed hydrogels.
Over the past years, nanotechnology-based devices
have been attractive tools for discovering optimally safe
and beneﬁcial drug candidates. Scientists have taken
advantages from various nanoscale delivery vehicles for
targeted and controlled drug release applications since
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Figure 1 A simple depiction of CDDSs at different time points.
Abbreviation: CDDSs, controlled drug delivery systems.
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nanoparticles can avoid immune system clearance and
penetrate cells and tissues where conventional delivery
systems cannot. Recently, many organic and inorganic
nanomaterials and devices have been utilized as delivery
systems to develop potential therapeutic modalities.
Additional advantages of these vehicles can be improving
drug therapeutic activity through prolonging drug half-life,
enhancing hydrophobicity of drugs, reducing potential
immunogenicity and more importantly, releasing drugs in
a controllable and limited manner.20,21
Polymeric nanoﬁbers ranging from 50 to 1000 nm, in
particular, due to their unique properties (including speciﬁc
surface area per unit mass, greater porosity with small pore
sizes, signiﬁcant mechanical properties based on architectural arrangement and magniﬁcent ﬂexibility) are of great
interest to release drugs locally and slowly for numerous
biomedical applications, such as wound dressings.22,23
Nanoﬁbrous mats are also very good candidates for sustained
release applications for antibiotic, antibacterial, antifungal or
anticancer agents as they can beneﬁcially encapsulate drugs
in dressings and/or scaffolds.24
Polymer nanoparticles (NPs) have also revolutionized
the ﬁeld of CDDSs due to their larger surface areas per
volume compared to conventional particles leading to
enhanced drug encapsulation, better loading capacity, stability, local release and can be easily attached to a variety
of compounds.25 It is interesting to mention that drug
delivery is directly affected by the morphology and
shape factors of the nanoparticle systems. Moreover, it is
a proven fact that particles of nanometer to sub-micron
size signiﬁcantly outperform microparticles in DDSs.
While larger particles possess large cores contributing to
faster polymer degradation permitting drugs to be better
encapsulated and slowly diffuse out, smaller particles with
their greater surface areas allow the drug to be at or near
the particle surface, causing even faster drug release.
Furthermore, the geometry of the nanoparticle can inﬂuence drug release. For instance, discs and rod-shaped
nanocarriers have superior blood circulation properties
over spherical particles, enabling longer circulation times
and better targeting.26
In the majority of these situations, drug loaded nanoﬁbers have emerged remarkably in favor of a blended polymeric solution, resulting in sustained and burst release.27
Biocompatible and biodegradable synthetic polymers
(such as PLGA, PLA, PGA, poly (vinyl alcohol) PVA,
poly (ε-caprolactone) (PCL), poly (ethylene glycol)
(PEG), poly (L-lysine) (PLL) and polyphosphoesters
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(PPEs)) and natural ones (namely cellulose, CS, starch
and gelatin) have opened many avenues for improving
medical and pharmaceutical applications, and when fabricating them at the nanoscale, they have revolutionized
controlled drug delivery research.28,29

Polymeric Hydrogels and Micelles as
Drug Delivery Vehicles
Hydrophilic gels, so-called hydrogels, are a crosslinked network of polymers of considerable absorbent compositions,
produced by both natural and synthetic polymers. The distinctive characteristic of hydrogels include their soft material
environment due to their high degree of hydrophilicity,
which promotes the uptake of water.30,31 This high water
content makes hydrogels very promising for the signiﬁcant
loading of hydrophilic drugs for CDDS applications which
mimics biological tissues (Figure 2).32 Furthermore, their
porous conﬁguration allow drugs to be loaded into the gel
matrix giving rise to drug release gradually based on the
diffusion coefﬁcient of the small and/or macro molecule in
the gel network.19 For more information on hydrogels, we
refer the reader to a comprehensive review by Li et al,9 as
here we emphasize only their nano aspects.
Three-dimensional hydrogels—such as copolymeric
hydrogels—bring a number of exceptional applications in
CDDSs.33–35 For instance, enzyme-mediated redox chain
initiation including glucose oxidase (GOX) was used to
build three-dimensional hydrogels through stable aqueous
conditions under ambient temperature and atmospheric
circumstances. This process was completed via an easy
interfacial polymerization approach for producing nanometer-scale constructs and consistent PEG-based hydrogel layers safe for use after incubation in water for 16
weeks. Moreover, such three-dimensional hydrogel layers
were able to load both biological agents and ﬂuorescent
nanoparticles predicted to be a suitable technique for
CDDSs.36 This study revealed that three-dimensional
hydrogels could be a remarkable approach for evaluating
controlled drug release proﬁles owing to the fact that they
possess a uniform, conformal coating and multilayer nano
structure. Besides, in order to obtain a high degree of
swelling for the beneﬁcial release of drugs in a controlled
manner, it is highly recommended to use synthetic nanostructured polymers over natural ones, as they possess
much better water-soluble properties and their nanoscale
properties provide for increased surface area which leads
to greater control.37
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Figure 2 Drug release from hydrogels: (A) drug is released by dissolving from the hydrogel, (B) drug is incorporated into the hydrogel to maintain its native structural
integrity and function, (C) stimuli-responsive hydrogels loaded with a drug as a drug carrier, and (D) entrapment of a drug in a degradable hydrogel allowing the drug to
diffuse out of the hydrogel.

Polymeric micelles have been a superior strategy in
tackling the delivery of poorly water-soluble drugs in a
controlled manner at target sites. They are formulated by
the spontaneous self-assembly of amphiphilic block copolymers in an aqueous solution.38 Polymeric micelles are
naturally nanostructured and provide for much better stability, tailorability and no toxicity. Because of their special
core-shell structure, the hydrophobic part paves the way
for the encapsulation of hydrophobic drugs. The hydrophilic part, however, could protect the hydrophobic section
from the biological invasion owing to its brush-like nanostructure. With respect to the hydrophobic nature of the
micelle core, water-insoluble drugs can be encapsulated
and solubilized in the micellar core by either chemical
conjugation or physical entrapment to reach their desired
target (Figure 3).39 Several studies have reported the progression of polymeric micelles in CDDSs.40,41

The State of the Art of Nano
Polymer Blends in CDDSs
Polymer blends are simple and successful combinations of at
least two polymers to provide a new and economical excipient with different physical properties without the
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preparation of particular copolymers.42,43 They provide
new products with various applications in the pharmaceutical
and biomedical ﬁelds. This straightforward and time-saving
approach can combine the ﬂavor of different polymers and
beneﬁt not only drug and gene delivery, but also many
technological advancements such as organic solar cells,
thick plastics and membrane separation.44,45 The blending
of polymers can reduce the undesired side effects of many
drugs, particularly, those biological agents in which drug
release is very important. In that way, the timing of drug
release and drug dosage should be regulated and improved.
However, in terms of drug delivery, some key factors should
be taken into consideration, including intrinsic miscibility
among two polymers, the interaction between the active
pharmaceutical ingredients (API) with polymers and the
critical situation of the environment during storage.46
Fundamentally, drug delivery in the presence of blended
polymers is a complicated process suggested by three
mechanisms: polymer relaxation, degradation, and diffusion
(Figure 4).47
Different classiﬁcations of biological products, ranging
from proteins to antibodies, can be incorporated into copolymers based on their properties either indirectly or physically
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Figure 3 Polymeric micelles in CDDSs. Hydrophilic block copolymers can establish micelles in an aqueous solvent with a hydrophobic core sterically stabilized by a
hydrophilic shell. The drug is localized in the hydrophobic core separated from the outside environment by a hydrophilic shell.
Abbreviation: CDDSs, controlled drug delivery systems.
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Figure 4 Schematic illustration of drug release from a typical nanoparticle/nanocomposite/polymeric based material. Notes: Reprinted with permission Merino S, Martin C,
Kostarelos K, Prato M, Vazquez E. Nancsite hydrogels: 3D polymer–nanoparticle synergies for on-demand drug delivery. ACS Nano. 2015;9(5);4686-4697. Copyright 2015
American Chemical Society.211

and even be chemically surface-immobilized.49 Even though
the properties of natural polymers are less similar to synthetic
polymers, there has been some evidence of the interaction
between them, most of which have led to polymer hydrogel
compounds as three-dimensional heavy networks formed by a
polymer backbone, water and crosslinking agents in CDDSs.50

International Journal of Nanomedicine 2020:15

Indeed, hydrogels are produced by hydrophilic monomers
with crosslinkers used for a wide variety of medical applications, particularly for controlled drug release in vivo and in
vitro.51 Polymer combinations are usually used for enhancing
the poorly water-soluble delivery of pharmaceutical
ingredients.
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The Aim of Using Nano Polymer
Blends in CDDSs
The reasons why polymer blending outclass single polymers could be the reduction or even removing of long and
costly procedures necessary for producing new polymers
that not merely lead to new and great properties, but also
improve material processability and polymerization steps.52
Besides, polymer blending has made a breakthrough in
tailoring the important disadvantages of polymers such as
biodegradability, physico-mechanical, poor mechanical and
thermal properties. For instance, the biodegradability of
polymer matrices can be improved through blending of
biodegradable and non-biodegradable polymers and changing their composition.53,54
Generally, polymer blends can be categorized as (i)
miscible, (ii) compatible and (iii) immiscible. As miscible
blends do not provide preferred properties, their applications in industry is not favorable. The signiﬁcant feature of
polymer blends is their phase behavior in which polymers
mostly produce immiscible and incompatible blends
resulting in a coarse phase morphology with a particulate
minority phase dispersed in a matrix and poorly distributed. Moreover, polymer mixtures are more likely to be in
two separate layers, like oil and water, owing to the
unfavorably low value of entropy. Therefore, morphologies of polymer blends are determined by their processing
and thermal history. After blending of two polymers, they
are prone to obtain a small-scale arrangement of the
phases, called the “microstructure”. The blend properties,
eventually, are greatly affected by the size scale of the
microstructure, giving rise to a pressing issue between
processing ﬂow conditions and microstructure. As a consequence, the compatibilization of polymer blends plays a
crucial role in altering the interfacial properties in an
immiscible polymer blend. The major advantage of this
approach can be a decrease in the interfacial tension coefﬁcient and the generation and stabilization of the satisfactory morphology.52,55–57 Among different compatibilizers,
the role of nanoparticles to improve the ﬁnal morphology
of the polymer blend has gained popularity.
Nanostructured blends achieved by cross-linking the
major phase and/or minor phase are of ideal interest in
producing materials with smart properties. The myriad of
beneﬁts of nanostructured polymeric blends in CDDSs
may be better device fabrication, modiﬁcation of device
characteristics, enhanced drug loading and the use of the
dispersed phase domains for improved drug release
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properties.58 Among nanostructured materials, nanostructured hydrogels have received much attention in the ﬁeld
of nanotechnology.59 The rate of drug release from nanostructured hydrogels can be controlled through various
approaches, such as modifying the cross-linking density
or controlling the ratio of hydrophilic to hydrophobic
monomers.60
The compositions of different types of polymers—such as
PLGA, PLA, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), surfactants, etc.—can increase the
rate of drug water solubility and their release.61,62 Further,
creating such polymers to be nanostructured can increase surface area and increase water solubility. For instance, Liu et al
utilized an ethylene-vinyl acetate copolymer (EVA) blended
with PLA and PEG as a stent coating drug carrier for delivering paclitaxel (PTX), and as a result, they demonstrated that
these blends released PTX in a highly tunable and controlled
way.63 In another example, hydroxypropyl methylcellulose
acetate succinate (HPMCAS) was blended with dodecyl
(C12)-tailed poly (N-isopropylacrylamide) (PNIPAm) for
improving low water-soluble drugs, such as phenytoin.45 It
should be noted that among synthetic and natural polymers
used in drug delivery, synthetic–natural polymer blends have
attracted more attention than either synthetic–synthetic or
natural–natural polymer blends providing a satisfying platform to combine mechanical and bioactive properties.48
With all of these considerations, the potential applications of polymer blends as carrier materials in CDDSs has
been inextricably bound with several difﬁculties in the
design and development of devices in comparison to
forms coated with just one group of polymers. However,
owing to advancements in CDDSs in the last two decades,
the optimal architecture and application of CDDSs with
tunable drug release proﬁles have been achieved.
The main aim of this review is to provide recent
developments in nano polymer blends with an emphasis
on controlled and sustained delivery, carrier fabrication,
drug loading efﬁcacy, and physicochemical properties.
Here, we make comparisons between the role of natural
and synthetic polymers in CDDSs. In particular, the manner of controlled release from CS, cellulose, and starch, as
well as PLGA, PLA, and PGA will be discussed from
research over the last ﬁve years in the sections that follow.
In most sections, we bring additional applications of different nano polymer blends to a diversity of drug delivery
systems and medical devices through succinct tables. We
give particular attention to approaches for CDDSs for
hydrophilic drugs that are highly loaded in their ﬁber
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forms. Furthermore, future potentials and challenges of
nano polymer blends are also discussed.
In Table 1, we provide advantages and disadvantages
of the above natural and synthetic polymers.

Types of Polymers Used in CDDSs
Natural Polymers
Natural polymers—which are fundamentally polysaccharides—play a versatile role in medical applications, including CDDSs, regarding the regulation of the dosage form
and improvements in physicochemical parameters. They
serve as excipients in pharmaceutical companies due to
their low cost, biodegradability, biocompatible structures,
availability and having safe properties.64,65 These polymers are water-soluble, biogenic, enzymatically degradable, chemically ﬂexible and consist of large molecules
which originate from nature—namely plants, microorganisms, and animals.16 Furthermore, these polymers can be
classiﬁed into two major groups: (1) protein polymers,
such as collagen and gelatin, and (2) polysaccharides,
like CS, glycogen, cellulose, and starch.66 During recent
years, there has been a great deal of interest in biodegradable polysaccharides for CDDSs exploited as drug carriers
or enhancers of the viscosity in liquids or emulsions.8

Current studies on biocompatible and biodegradable natural polymers have led to a considerable evolution of more
novel types of wound dressings and applications in the biomedical area. Among them, natural polysaccharides—such
as CS, cellulose, and starch—have garnered attention
because of their organized structures, and thus, they are
preferable for producing polymer-based composites and biopolymers. This section aims to demonstrate recent progress
in CS, cellulose and starch blends and their application in
CDDSs.

Applications of Chitosan (CS) and Its
Blend Derivatives in CDDSs
CS is the second most plentiful polysaccharide with abundant
bio-applications. It can be produced from the alkaline
N-deacetylation of chitin but it is also a biopolymer found
in insects, fungi and more greatly, in the shells of
crustaceans.67,68 With respect to medical applications, CS
has gained popularity because of its great properties, speciﬁcally in its ability to blend with polymers. Therefore, CS
can blend with numerous natural and synthetic polymers,
displaying a diversity of features that enhance its utility as a
drug delivery vehicle based on its mucoadhesive nature.69
Recently, CS blends have been successfully utilized for drug

Table 1 Advantages and Disadvantages of the Mentioned Natural and Synthetic Polymers
Polymer
Natural (CS, Cellulose, and
Starch)

Synthetic (PLGA, PLA, and
PGA)

Advantages

●
●
●
●
●
●
●
●
●
●
●
●

Water solubility enhancer
Less/non-toxic
Good transparency and swelling
Biocompatible and biodegradable
Capable of incorporating with drugs
Readily available
Low immunogenicity
Inertness

●
●
●
●
●
●

Ref.
26,64–

Microbial and heavy metal contamination
Hydration uncontrolled rate

66

Batch to batch variation
Slow rate of production
Complicated extraction procedure
Variable in natural materials derived from animal
sources

Less side effects
Cheaper
Easily chemical modiﬁable
Abundance naturally

● Easy tailoring
● Better mechanical and chemical
stability

●
●
●
●
●
●

Disadvantages

Higher reproducibility
Tunable

● Lack of intrinsic biocompatibility and bioactivity
● Possible to cause toxicity, inﬂammation, and immune

67–70

response

● Difﬁcult and expensive synthesis procedure
● Water solubility problems

Speciﬁcity and selectivity
Easily degradable
Better conjugation properties
Clinically applicable

Abbreviations: CS, chitosan; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic acid); PLA, polylactic acid; PGA, poly(glycolic acid).
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and vaccine delivery,70,71 cranial defects,72 anti-cancer
activity,73,74 anti-adhesion therapy,75 antibacterial activity,76
anti-aging therapy77 and anti-inﬂammatory wound dressing
activity.78 As with the aforementioned polymers, nano CS
possesses increased surface area per volume compared to
conventional CS, and thus has even greater biological
properties.
For wound healing applications, stimuli-responsive CS
and poly (N-vinyl-2- pyrrolidone) (PVP) were blended
with 74% neutralized poly ascorbic acid (PAA). The
obtained hydrogels showed not only antimicrobial properties against E. coli but also demonstrated signiﬁcant behavior for delivering silver sulfadiazine with approximately
90% of release in a controlled manner within 80 min.79
Texier et al showed intermolecular interactions between
CS and PEG sponges as a chemical crosslinking of the
PEG network in the CS matrix via nucleophilic thiolyne
addition. The morphology of the composite demonstrated
that these novel crosslinked-sponges possess high stability
with a porous structure for topical drug delivery at physiological conditions.80 In a recent study, CS and PVP
were combined to effectively deliver betamethasone-17valerate (BMV) for treating recurrent aphthous stomatitis
(RAS). The existence of PVP with CS can enhance both
thermal stability and swelling ratio for the release of BMV
at roughly 80%.81 Polymer blending here enabled PVP
with a higher swelling ability to increase tensile strength
leading to an efﬁcient mucoadhesive drug delivery system.
In another study, Jesus and colleagues developed a
blended material produced by CS and PCL NPs in order
to improve the controlled release of vaccine, protein, and
antigen, as well as reduce their cytotoxicity. Notably, over
a span of 6 months, ovalbumin (OVA) adsorption on PCL/
CS NPs led to an expected loss of protein ellipticity along
with an alteration to a marked β-sheet content, but it did
not induce protein-unordered conformation. The release of
the drug was reported over 6 h.70 Carboxymethyl CS
(CMCS) was blended with gelatin, a biodegradable and
biocompatible polypeptide, as a controlled release polymeric hydrogel, in order to analyze the release of 5Fluorouracil (5-FU). The blended microspheres were
examined with different analytical techniques to understand the interaction of the polymer and 5-FU. As a result,
the in vitro release of 5-FU increased to 12 h at a physiological pH,82 with an expected enhancement for
nanospheres.
To tackle problems of infection and traumatic musculoskeletal injuries, Berretta et al developed a blend of CS and
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PEG pastes to provide biocompatibility, biodegradability and
the local delivery of vancomycin and amikacin to a larger
distribution of eluted antibiotics to prevent or even treat
musculoskeletal wounds and bone infections. Therefore, preliminary studies showed satisfying results for the CS/PEG
copolymers with the mentioned antibiotic drugs, which
resulted in degradability, biocompatibility, injectability and
prevention of infection for musculoskeletal-type wounds.83
The injectable, cytocompatible and biodegradable gels based
on an easy blending of 4.0% carboxymethyl hexanoyl CS
(CHC) with 4.0% hyaluronic acid (HA) was described.
These injectable in situ gels were not made by high temperature nor crosslinking reagents and förster resonance energy
transfer (FRET) controlled the mechanism of gel formation.
With this blend, a turbid colloidal suspension and subsequently supermolecular hydrogels were obtained immediately to sustain and provide pH-dependent delivery of
berberine as an anti-apoptotic and anti-arthritis herbal medicine. In vitro degradation was evaluated through dipping of
the gels in various buffer solutions at 37 °C of hyaluronidase
and lysozyme. The weight loss ratio of the gels in pH 6.0
buffer was 7.8%, 40.5%, 45.1% and 62.1% in the buffer and
lysozyme, hyaluronidase and both enzymes, respectively.
Sustained drug delivery was achieved at pH 6.0 showing
that the gel was more stable at pH 6.0. Moreover, the gels
greatly swelled within a day, preceded by a sharp reduction in
mass in a pH 7.4 buffer. Besides, the drug-loaded blends kept
chondrocytes safe against sodium nitroprusside-induced
apoptosis and arthritis resulting in an improvement of the
anti-apoptotic efﬁciency of berberine. From another perspective, another research group focused on preparing LbL
assembled multilayer ﬁlms using the above mentioned feature of CMC and chitosan, which helped them study the
chemistry of those biocompatible polysaccharides by investigating both cross-linked and non-cross-linked nanostructures (Figure 5).84
Moreover, Rokhdadeh et al formulated pluronic F127/
CS blend microspheres and glutaraldehyde as a crosslinker. These blended compounds showed high physical
activity and drug-polymer harmony in comparison to CS
microspheres with excellent mucosal DDSs. It is noteworthy to indicate that the release proﬁle of the 5-FU as
a model drug improved to 1 day.85 More recently, a novel
composite developed by Anirudhan et al consisted of
blends of biodegradable thiolated CS-PEG contained
with medical clay (MMT), named TCS-PEG/MMT, and
was used for the oral drug delivery of insulin.
Consequently, after 8 h, almost 70% of insulin was
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Figure 5 (A) Chemical structures of chitosan and carboxymethyl cellulose sodium salt. (B) Schematic illustration of the cross-linking-induced structural change of the LbLassembled CMC/CHI multilayer ﬁlm and its effect on the loading of drugs with different molecular weights.
Notes: Reprinted with permission Park S, Choi D, Jeong H, Heo J, Hong J. Drug loading and release behavior depending on the induced porosity of chitosan/cellulose
multilayer Nanoﬁlms. Mole Pharm. 2017;14(10):3322-3330. Copyright 2017 American Chemical Society. 84
Abbreviations: CMC,carboxymethyl hexanoyl chitosan; LbL, Layer-by-Layer.

released at a basic pH of 7.4, which revealed the controlled
release of the drug.86 Tolbutamide (TOL), a signiﬁcant
hypoglycemic drug, was released in a controlled manner
loaded with CS/PLGA NPs with the solvent evaporation
method. Thermal gravity analysis (TGA) and transmission
electron microscope (TEM) proved that not only did this
copolymer enhance the bioavailability of the drug, but it
decreased TOL dosage. Additionally, TOL was released by
CS/PLGA-TOL NPs at a pH of 7.4 and in a phosphate
buffer solution (PBS) in a sustained manner.87
Arya et al utilized curcumin (Cur), a herbal anti-cancer
drug, loaded PLGA NP surfaces coated with a blend of CS/
PEG in order to increase bioavailability and reduce limitations in conventional chemotherapy. These Cur nanoparticles

International Journal of Nanomedicine 2020:15

showed a controlled release rate of Cur after 6 days, followed
by a biphasic phenomena, together with higher cytotoxicity,
improved anti-migratory, as well as anti-invasive and apoptosis-inducing ability of the CS/PEG blend in various pancreatic cancer cell lines in comparison with the native
counterpart.73 In another study, the controlled release behavior of Metformin (Met) was reported by Shariatinia et al.
This group developed a highly efﬁcient ﬁlm from a blend of
CS and poly (ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene) consisting of mesoporous MCM41 or MCM-41-APS (APS=aminopropylsilane) nanoparticles for the controlled release of Met. The release of the
drug increased considerably within 22–24 h (burst release),
after which the release of the drug was slowed to release over
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15 days (controlled release). Moreover, the ﬁlm including
4% MCM-41-APS and 10% Met revealed improved tensile
strength, hydrophilicity, biocompatibility, and drug release.88
In Table 2, additional applications of CS blends are summarized for the controlled release of various drugs.

Applications of Cellulose and Its Blend
Derivative in CDDSs
Cellulose is a ﬁbrous and water-soluble organic material with
a linear homopolymer of β-1,4-linked anhydro-D-glucose
units having abundant hydroxyl groups, which possess a
high ability to blend with different kinds of materials.89
Cellulose and its derivatives (such as microcrystalline cellulose (MCC), ethyl cellulose (EC), methylcellulose (MC),
HPMC, HPC, carboxymethyl cellulose (CMC), and several
other forms) have been widely used in CDDSs as signiﬁcant
carriers.90–92 Blends of different cellulose derivatives with
other excipients participate in coating and enteric coating
roles in pharmaceutical industries by releasing biological
molecules in a controlled manner.93
The effect of blending cellulose and PEG for loading
vitamin C as a typical drug was reported by Shen and colleagues. In this experiment, pH and temperature responses were
conducted and an effective controlled drug release was
reported. An interesting point in this report is that it used
cellulose and showed pH responsive-based drug release in

multi-pulses, which means that according to the Grayson
et al experiment,94 this blend could be regarded as a valuable
device for CDDSs.95 β-cyclodextrin (β-CD) and CMC hydrogels were blended for the controlled release of the antiviral
drug, acyclovir. The degree of swelling and crystallinity, which
are two remarkable factors for drug release,96 demonstrated
improved drug loading and sustained release capability.97
Here, nanomedicine has also provided signiﬁcant improvements. Speciﬁcally, electrospun nanoﬁbers have extensively
been used in CDDSs due to their particular advantages as
highly effective nanoﬁbers.98,99 Electrospinning is a ﬁber production process that makes micro/nanometer-sized polymeric
ﬁbers. Their applications in sustained drug release can be
achieved if surface modiﬁcation is performed on blends of
electrospun ﬁbers.100 It needs uncomplicated equipment compared to other ﬁber fabrication methods, such as wet chemistry
methods and molecular beam lithography. Because the process
can create diverse polymer construct properties such as compatibility, high surface to volume ratio, high porosity, and
straightforward encapsulation of therapeutic molecules, it has
been widely used in CDDSs speciﬁcally in regenerative medicine and wound dressings. The electric force in electrospinning is used to control the surface tension and polymer
solution viscosity to make electrospun ﬁbers.101,102
Recently, El-Newehy et al developed a polymer blend
made of HPC with PVA and PVP to release diclofenac

Table 2 Other Applications of CS Blends in CDDSs
Loaded Active

Blend Composition

Duration of Release (Days)

Therapeutic Effect

Ref.

ASCs

CS/Gelatin

5

Promotion of angiogenesis in ischemic disease

89

BFGF & BSA
Deferoxamine

CS/PVA/Gelatin
CS/HA

4 & 25
10

Wound healing
Promotion of angiogenesis

90

Dopamine and metronidazole

CS/Gelatin

>20 & >12

Treatment of Parkinson’s disease

92

Potassium nitrate
Naproxen

CS/Starch
CS/PEG

14
1

Modulate fertilizer release
Wound healing

93

TCH

CS/SA

14

Wound healing

95

Lupeol
Methyl Orange

CS/Gelatin
CS/Cyclodextrin

1
1

Wound healing
Favorable for drug carriers

96

TCH

CS/PEG/PVP

2

Wound healing

98

Levoﬂoxacin
Gentamicin

CS/PVA
CS/PVA

3
2

Effective for sustained drug release
Wound healing

99

BMP-2

CS/HA

>30

Potential for bone and soft tissue engineering

101

Deferoxamine
Oﬂoxacin

CS/SA
CS/PAM

10
1

Treatment of iron dysregulation diseases
Favorable for antibacterial activity

102

BSA

CS/SA

17

Potential for soft tissue engineering

104

Component

91

94

97

100

103

Abbreviations: CS, chitosan; PEG, polyethylene glycol; ASCs, adipose-derived stem cells; Bfgf, basic ﬁbroblast growth factor; HA, hyaluronic acid; TCH, tetracycline
hydrochloride; BMP-2, bone morphogenetic protein-2; BSA, bovine serum albumin; PAM, polyacrylamide; SA, sodium alginate; PVA, polyvinyl alcohol; SA, salicylic acid;
CDDS, controlled drug delivery system; PVP, polyvinyl propyl.
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sodium (DS) as a model drug based on electrospun nanoﬁbers. In this study, in vitro entrapment efﬁciency and the
sustained release of DS were controlled by UV spectroscopy when loaded into electrospun nanoﬁbers of HPC
with PVA and PVP, at a pH of 7.4 and at body temperature;
in the ﬁrst two hours, the amount of the DS released from
the electrospun ﬁber was 63, 61, 58, and 46% of its DS
content from HPC/PVA 100/0, 75/25, 50/50 and 25/75,
respectively, whereas it released 85, 69, 63, and 57% of
its DS content after three hours, respectively. However, the
rate of release was diminished by increasing the PVA concentration because PVA in the nanoﬁber mats controls the
DS release by forming hydrogen bonds with DS. Therefore,
the blends of PVA and PVP with HPC enhanced the
mechanical properties of the HPC nanoﬁbers mats which
could clearly be fruitful for biomedical therapy.103

HC

In terms of a nanomedicine approach, CMC and PVA
were blended and loaded with ZnO nanoparticles and erythromycin (EM), the selected antibacterial drug (both alone
and in combination), for achieving a more beneﬁcial antibiotic activity with regards to a synergistic effect.
Electrospinning procedures and crosslinking with 2% glutaraldehyde vapor and a 3% AlCl3 alcoholic solution were
used for fabrication. Therefore, EM-loaded PVA-CMC/ZnO
nanocomposite mats demonstrated a good ability for not
only sustained drug release but also for wound dressings
owing to their satisfactory antibiotic efﬁcacy. It should be
noted that the release of EM was completed after three days
(another CMC delivery system is presented in Figure 6).22
Moreover, the controlled release of donepezil hydrochloride was investigated by Gencturk et al. They developed
potential and non-toxic electrospun polyurethane/HPC (PU/

CMC

Drug molecules

Figure 6 Schematic representation of the preparation of a carboxymethyl cellulose (CMC) based drug delivery system.
Notes: Reprinted with permission Lai, WF, Shum HC. Hypromellose-graft-chitosan and its polyelectrolyte complex as novel systems for sustained drug delivery. ACS
Applied Materials & Interfaces. 2015;7(19):10501-10510. Copyright 2015 American Chemical Society.108
Abbreviation: CMC, carboxymethyl cellulose.
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HPC) nanoﬁbers for transdermal CDDSs according to in vitro
preliminary permeation data. Approximately 90% of donepezil hydrochloride in the nanoﬁbers released slowly over 6h.104
Zhu et al developed smooth and cylindrical nanoscale ﬁbers of
poly (N-isopropylacrylamide) (PNIPAAm) and EC blends
loaded with ketoprofen (KET) with considerable intermolecular interactions between them. The intermolecular interactions between the drug and blend were very good and KET
release was reported at different ratios. Heating changed
unexpectedly as observed from the water contact angle on
the PNIPAAm and blend nanoﬁbers, and the ﬁbers underwent
a fast hydrophilic/hydrophobic transition. At a 1:2 weight ratio
of PNIPAAm/EC in the ﬁbers, KET release at 25 °C was
much faster than at 37 °C owing to this drastic change in
properties. For the 1:1 ratio, the release rate from the ﬁbers
was relatively low at 37 °C. Finally, for the 1:4 weight ratio of
PNIPAAm/EC, the materials lost most of their thermoresponsive properties. But not only were these blended ﬁbers safe
and appropriate for cell growth, but more importantly, the
electrospun-blends of PNIPAAm/EC ﬁbers played a beneﬁcial role in the controlled release of poorly water-soluble drugs
for tissue engineering applications.105
Core-shell nanoﬁber drug carriers were reported via a
graft blending of NaCMC, poly (ethylene oxide) (PEO) and
methyl acrylate (TCMC) loaded with TCH to build TCMC/
PEO/TCH(CS) core-shell polymeric nanoﬁbers, which were
fabricated by coaxial electrospinning as a novel controlled
drug delivery system. Spectroscopy analyses demonstrated
that the release of TCH was slow and at a controllable rate
within 72 h. Additionally, core-shell TCMC4/PEO(CS)
electrospun nanoﬁbers exhibited outstanding antibacterial
effects against both gram-positive and gram-negative bacteria, as well as good cell viability. For toxicity and biocompatibility of the TCMC4/PEO/TCH(CS) and TCMC4/
PEO(CS) core-shell electrospun nanoﬁbrous mats, an MTT
assay was used and showed that cell viability on the nanoﬁbrous reached 100% after a day. While after two days, the
TCMC4/PEO(CS) revealed no cytotoxicity and the
TCMC4/PEO/TCH(CS) nanoﬁbers demonstrated a decrease
in the viability of human ﬁbroblasts (HDF) reporting that
the released TCH at 24 h and 48 h affected cell viability.106
Further, different quantities of cellulose nanocrystals
(CNCs) were blended with gelatin hydrogels with glutaraldehyde used as a crosslinker, due to its high reactivity
toward the -NH2 group of gelatin, and on account of the
weak mechanical properties of gelatin. Figure 6 shows a
schematic of a typical preparation process of a nanocarrier
based on carboxymethyl cellulose (CMC) based on the
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reaction between different functional groups as well as
loading of the drug into the main core of the nanocarrier
along with conjugation to the surface. In another study,
different proportions of CNCs (0.5, 5, 15, 20 and 25%)
were selected to investigate the effects of CNCs on the
swelling ratio, as well as dynamic mechanical properties
of gelatin-based hydrogels to make semi-interpenetrating
polymer networks (semi-IPNs). Semi-IPNs ameliorated
not only the mechanical properties of the hydrogel and
drug release, but it also controlled swelling ratio.
Theophylline was incorporated as a drug model in this
study. As a consequence, the highest swelling ratio and
drug release and efﬁcacy were related to 5% CNC at pH 3.
Nevertheless, the best drug loading for sustained and controlled drug release was associated with 15% CNC. Drug
release rates continuously decreased with time owing to
the thickness of the hydrogel that acted as a diffusion
barrier. It should be noted that the hydrogel with the higher
swelling ratio resulted in higher drug release percentages,
and as a result, the 5% CNC-gelatin hydrogel showed the
highest drug release percentage while the 25% CNC-gelatin hydrogel showed the lowest drug release percentage.107
HPMC of diverse viscosities has been thoroughly used in
the pharmaceutical industry for the controlled release of drugs.
Its considerable swellability, hydrophilicity and non-ionic nature has paved the way for blending with various excipients, in
the form of hydrogels, to achieve the controlled release of
biological products.109–111 In this case, HPMC was blended
with different kinds of polymers, such as PVP,112 CS,113
EC,114 gelatin, and xanthan gum115 and in most cases, these
blends showed remarkable controlled release activity.116–119
Dharmalingam et al designed a combination of HPMC and
NaCMC in the presence of citric acid (CA) as a crosslinking
agent (citric acid crosslinked HPMC-NaCMC hydrogel ﬁlms)
in order to evaluate the controlled release of methylene blue
and TCH for wound healing applications. The loading efﬁcacy
for the drugs reversed for different ratios of CA at a pH 7.4 and
37 °C. Speciﬁcally, when the concentration of CA in the
hydrogel increased from 5 to 10 to 20%, the loading efﬁcacy
of methylene blue increased (approximately 35, 45 and 55%,
respectively), whereas the pattern for TCH was the complete
reverse (approximately 10, 8 and 6 %, respectively). Moreover,
this increase led to a reduction of the swelling ratio, the water
contact angle (surface hydrophilicity) and tensile strength of
the hydrogel ﬁlms, while the elongation at break (%) increased.
Additionally, both drugs released in a controlled manner for
more than 3 days, demonstrating that the HPMC/NaCMC
hydrogels were highly satisfactory not only for controlled
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drug release but for effective wound healing as an excellent
antibacterial agent.120
Similarly, atenolol-controlled release was investigated
by Lotﬁpour et al in an experiment with different concentrations of soluble and insoluble binary blended polymers,
including Eudragit RSPO, EC, and NaCMC with HPMC.
The controlled release proﬁle of atenolol from different
weight ratios of matrices containing the blends of HPMC
and other excipients was conﬁrmed with diffusion and
erosion processes, depending on the type of polymer and
concentration.121 Blends of HPMC with SA were also
investigated for the release proﬁle of three drugs: BSA,
Met, and indomethacin (IDM), with different molecular
weights and solubility properties. Due to the large pores in
the HPMC-SA hydrogels, small and water-soluble Met,
had a burst release within just 2.5 h. Nevertheless, other
drugs and BSA and IDM as two water-insoluble compounds had better-controlled release proﬁles in which the
macromolecular drug BSA had the best-sustained release
proﬁle for blockage by a semi-interpenetrating polymeric
network and IDM showed controlled release after 12 h.122
In Table 3, additional applications of cellulose blends are
summarized for their controlled release of various drugs.

Applications of Starch and Its Blend
Derivatives in CDDSs
Starch is a natural polymeric carbohydrate and is the most
abundant storage polymer used extensively in the pharmaceutical industry because of its high availability, affordability, and biodegradability.123,124 It is constituted by
amylose (typically 18–33%) and amylopectin (typically

67–82%), which are highly applicable for many pharmaceutical and food applications.125,126 Scientists have a
positive attitude towards developing starch-related compounds as magniﬁcent materials with advantages of
greater biocompatibility and non-toxicity.127
Importantly, however, native starch separated from
various sources has some signiﬁcant drawbacks such as
narrow shear and thermal resistance, thermal decomposition and a high proclivity for retrogradation.128 Therefore,
the combination between starch and other biodegradable
and biocompatible polymers has addressed these problems, making it enormously beneﬁcial in tissue engineering, drug delivery and for the effective release of
biologically active compounds.129 Different starch-based
DDSs have been projected for therapeutic effects and these
DDSs can be associated with various drug carrier
strategies.130
Blending starch and its derivatives (such as sodium starch
glycolate and pregelatinized starch) with both compatible
and non-compatible polymers can be an advantageous strategy in order to improve the properties and stability of starchbased ﬁlms.131 Many studies have reported the ability of
starch to blend with a variety of materials to advance ionotropically gelled multiple-unit systems for the enhancement
of drug encapsulation, swelling, stability and controlled
release of biological agents.132–136 Ayorinde et al reported
blends of natural starches with HPMC for orally dissolving
ﬁlms of amlodipine besylate (AB). They utilized Bambara
nut (BAM) and the African yam bean (AYB) starches separately blended with HPMC. AB was included by dispersion
and ﬁlms were made by solvent evaporation. The AYB/

Table 3 Other Applications of Cellulose Blends in CDDSs
Loaded Active

Blend Composition

Component

Duration of

Therapeutic Effect

Ref.

>2

Wound healing

123

Release (Days)

BSA

MC/HA

Ibuprofen

HPMC/Eudragit

1/2

Improve patient compliance

124

DS

HPMC/Cedrela gum

1/2

Highly suitable for sustained drug release

125

Furosemide

HPMC/EC

>1/2

Remarkable drug entrapment efﬁciency

126

Theophylline

HPMC/Psyllium

1/2

Suitable for sustained drug release

127

Cilostazol

HPMC/Carbomer

1

Improved plasma concentration and better bioavailability

128

Naproxen

EC/PVP

>3

Wound healing

129

Isoliquiritigenin

HEC/HA

1

Enhanced skin permeation of the drug

130

FDZ and Bismuth(III)

CMC/SA

1

Treatment of gastrointestinal disorders

131

BSA

CMC/HA

30

Potential for cell encapsulation, regenerative medicine, and tissue engineering

132

BSA

CNCs/SA

8

Potential as drug carriers and wound dressing

133

Soil Nutrients

Cellulose/CS

30

Beneﬁcial for agriculture and horticultural applications

134

Abbreviations: FDZ, furazolidone; CS, chitosan; PEG, polyethylene glycol; ASCs, adipose-derived stem cells; Bfgf, basic ﬁbroblast growth factor; HA, hyaluronic acid; TCH,
tetracycline hydrochloride; BMP-2, bone morphogenetic protein-2; BSA, bovine serum albumin; PAM, polyacrylamide; SA, sodium alginate; PVA, polyvinyl alcohol; SA,
salicylic acid; CDDS, controlled drug delivery system; PVP, polyvinyl propyl; HPMS, hydroxyl-terminated polydimethylsiloxane.
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HPMC, BAM/HPMC demonstrated high viscosity, and
among all ratios, it was the BAM/HPMC (1: 1) and AYB//
HPMC (2: 1) that most effectively released all of the AB
content within 30 h. This activity can be traced back to the
individual physicochemical properties of BAM and AYB
(such as thickness, variation of mass, disintegration time,
folding endurance, and surface pH) inﬂuencing the dissolution of the drug from ﬁlms and, thus, increasing AYB concentration for a better sustained drug release while drug
release was reduced with increasing BAM concentrations.137
Dual crosslinking (DC) has been exploited as a beneﬁcial
strategy for tailoring drug delivery approaches.138 The ionic
crosslinking and DC were evaluated as a novel mucoadhesive DDS by de Oliveira Cardoso et al. In this experiment,
blends of natural polysaccharides, gellan gum and retrograded starch hydrogels loaded with KET were proposed
resulting in hydrogels with various rheological and mechanical properties and improvements in texture, as well as sustained drug release rate.139 The blending of starch and gelatin
and their predominant effect on controlled drug release—for
methylthioninium,140 ascorbic acid141 and vancomycin
hydrochloride142—have been reported.
High amylose has a chemical reaction afﬁnity due to its
hydroxyl groups (esteriﬁcation, etheriﬁcation, and oxidation) that can modulate their solubility, swelling, ﬁlm and
gel formation and biodegradability rates.143 In this sense, a
crosslinked interaction between high amylose starch and
pectin incorporated by DS for additional applications in
CDDSs was reported by Soares et al. The analytical
results, including thermal analysis and X-ray diffraction,
showed that while both thermal stability and crystallinity
increased, the mechanical strength of the structures
reduced due to drug loading. If we consider the sufﬁx
WD and CD as the samples without a crosslinker and the
samples containing DS respectively, the greatest recovery
(R %) indicated that the larger the amount of pectin in WD
and CD samples they had (1:4 samples), the stronger and
more elastic gels that were achieved. Moreover, drug
loading did not qualitatively inﬂuence the rheological
behavior which remained as gels, contributing that the
extra drug can weaken the polymer network, and further
interactions between the DS and carboxyl groups of the
polymers could prevent hydrogen bonding.144
In another novel study, starch grafted with PEG
(starch-g-PEG) and disulﬁde crosslinked micelles through
lipoic acid (LA) loaded with the anti-cancer drug doxorubicin (DOX) were used for stimuli-responsive intracellular drug delivery. Another study, as is illustrated in
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Figure 7, used H40-star-PLA-SS-PEP as the main selfassembly polymeric structure for the preparation of the
nanocarrier with the ability of loading DOX on its structure, and also on the surface. By comparing this study with
the previous one, it can be concluded that in the absence of
reductive glutathione (GSH), only a small amount of DOX
could release, whereas, for the 10.0 mM of GSH, roughly
90% of DOX was efﬁciently released. Furthermore, the
disulﬁde crosslinked micelles demonstrated a quicker
DOX release in glutathione monoester (GSH-OEt) pretreated HeLa cells compared to non-pretreated and buthionine sulfoximine (BSO) pretreated cells, and as a result,
disulﬁde crosslinked starch-g-PEG micelles paved the way
for drug release.145,146
In a signiﬁcant study, Setti et al developed a stable emulsion comprised of MaterBi® (a blend of thermoplastic starch
and PCL) as the hydrophobic phase and SA as the hydrophilic
phase for the controlled delivery of two commercial drugs:
Neomercurocromo® and Cur. Homogenous polymer ﬁlms
were achieved by an ultrasonic processor without using any
surfactants. Different MaterBi®/alginate fractions were tested,
and ﬁnally, in vitro studies showed that these ﬁlms were able to
release both drugs separately and simultaneously in controllable rates compared to a pure PCL polymer. They made three
sample ﬁlms from the matrix of MaterBi®: (1) uncrosslinked
and (2) crosslinked 50 wt% alginate 50 wt% MaterBi® ﬁlms as
well as (3) 30 wt% alginate 70 wt% MaterBi®. Over a span of 3
hours, the sample (1) released more hydrophilic drugs
(Neomercurocromo®) while for (2), both drugs were released
in lower amounts than their particular counterpart and ﬁnally
for (3), Cur release was lower whereas for the
Neomercurocromo®, release increased. Moreover, cell viability assays conﬁrmed the biocompatibility of the ﬁlms and
suitability for superﬁcial cell proliferation against human dermal ﬁbroblasts in adult cells, and even for applications in
wound healing and in the ﬁeld of hygienic packaging of special
pharmaceutical products.147
The superior advantages of starch nanocomposites —
in comparison to conventional composites — include their
optimal thermal, renewability, biodegradability, and
mechanical and barrier properties, which have been widely
used in the pharmaceutical industry as coating materials
for CDDSs. However, our strongly held belief is that more
research should be conducted for improving their controlled and local release area focussed on the physicochemical properties of starch and how to manufacture
and make starch nanoparticles.
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Figure 7 Illustration of Reduction-Stimulus Micelles Based on H40-star-PLA-SS-PEP for Intracellular DOX Release Triggered by Glutathione (GSH) Tripeptide.
Notes: Reprinted with permission Liu J, Pang Y, Huang W, et al. Bioreducible micelles self-assembled from amphiphilic hyperbranched multiarm copolymer for glutathionemediated intracellular drug delivery. Biomacromolecules. 2011;12(5):1567-1577. Copyright 2011 American Chemical Society.146
Abbreviations: DOX, doxorubicin; GSH, glutathione

Synthetic Polymers Used in CDDSs
The role of synthetic polymers is of greatest importance in
CDDSs as both a polymeric drug itself or as a carrier for
small molecule drugs/bio-macromolecules, as such proteins
embrace a signiﬁcant function in releasing a drug, peptide or
oligo or poly (nucleic acid) and can be regarded as stimuliresponsive polymers.17 Several studies have focused on
using synthetic polymeric matrices in many biomedical
industries due to their remarkable physical, resistance and
mechanical properties.127,148 It is worth noticing that in the
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case of polymer blending, natural polymers often do not
show gratifying results because of their preparation problems; thus, synthetic polymers are more favorable than
natural polymers in many cases.149 Among those used for
the sustained release and CDDSs, PLGA, PLA, and PGA
have been emphasized more, owing to their approval by the
US Food and Drug Administration (FDA) and the European
Medicines Authorities (EMA) for human use.150 It should be
mentioned that among all synthetic polymers, PEG has been
blended more with the above compounds because it can
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increase hydrophilicity, avoid immune system clearance and
provide a controlled release time, and in this way, much work
has been published.151
The aforementioned polymers are usually blended with
natural polymers to produce new hybrid products with
suitable physicochemical and thermo-mechanical properties
for promoting their fabrication into biomedical devices for
prolonged release systems,152,153 which prevent fabrication
and handling issues for medical applications.48 Novel synthetic polymers are being increasingly used in pharmaceutical sections as coating materials that provide for adequate
mechanical properties and better polymeric electrospinnability. Over the past years, modiﬁed synthetic polymeric
hydrogels have been blended with some natural polymers to
achieve advanced biopolymers, which have paved the way
for CDDSs. In this section, we illustrate the recent applications of PLGA, PLA and PGA and their blends with different excipients in numerous biomedical devices.

Applications of PLGA Blends in CDDSs
PLGA, a polyester of hydroxy acids, is one the most biocompatible, biodegradable and injectable polymers approved
by the FDA for many biomedical and therapeutic applications, ranging from DDSs to tissue engineering.154–156
Although PLGA is a glassy synthetic polymer, it has a
quite rigid structure along with remarkable mechanical
strength, permitting its use as CDDSs. Besides, PLGA copolymers possess high ratios of lactic acid which are less
hydrophilic than functional groups in PGA, absorbing less

water and consequently are more slowly degradable. Most
importantly, PLGA hydrogels degrade in a dynamic process
through hydrolytic cleavage of its poly (ester) backbone.157
To enhance the efﬁcacy of PLGA in CDDSs, many modiﬁcations have emerged, such as PLGA copolymers containing
blocks and alternating polymers through different hydrophilic
moieties—namely PEG or PEO.158
However, PLGA has brittle and low elongation characteristics, so the blending of PCL with PLGA has emerged for
developing nanoﬁbers with sufﬁcient ﬂexibility, good porosity, slow degradability and a better biological nature.159
Individually controlled release of some hydrophilic antiretroviral drugs—including Tenofovir (TFV), Raltegravir
(RAL), Maraviroc (MVC) and Azidothymidine (AZT)—
was accomplished in vitro through uniaxial electrospun
PLGA/PCL nanoﬁbers. By utilizing representative scanning
electron micrographs (SEM), different ratios of compositions
demonstrated a shift in drug release from a burst to sustained
release, as ﬁbers with a high PCL concentration showed fast
release (24 h), while ﬁbers with high PLGA content could
ameliorate limitations for the sustained release of TFV (30
days). In another study, scientists showed that different preparation procedures could lead to different surface morphologies, and in the following, different properties and
biomedical applications. For instance, the addition of metal
nanoparticles (such as Ag) or even metal salts into a polymeric structure as a dopant in the ﬁrst phase of synthesis and
in the last phase of synthesis can create two different surface
morphologies of an obtained scaffold (Figure 8).160,161
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Figure 8 Schematic illustration of the preparation procedure of PP-pDA-Ag-COL scaffolds. PLGA/PCL scaffolds were prepared by electrospun technology. Ag nanoparticles
were in situ reduced by polydopamine and then coated by collagen I.
Notes: Reprinted with permission Qian Y, Zhou X, Zhang F, Diekwisch TGH, Luan X, Yang J. Triple PLGA/PCL Scaffold Modiﬁcation Including Silver Impregnation, Collagen
Coating, and Electrospinning Signiﬁcantly Improve Biocompatibility, Antimicrobial, and Osteogenic Properties for Orofacial Tissue Regeneration. ACS Appl Mater Interfaces.
2019;11(41):37381-37396. Copyright 2011 American Chemical Society.161

4378

submit your manuscript | www.dovepress.com

DovePress

International Journal of Nanomedicine 2020:15

Dovepress

Maghsoudi et al

(i)
(ii)
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Figure 9 In vitro sustained cumulative release of DOX from starch-g-PEG/LA.
Notes: Reprinted with permission from Jin F, Liu D, Yu H, et al. Sialic acid-functionalized PEG–PLGA microspheres loading mitochondrial-targeting-modiﬁed curcumin for
acute lung injury therapy. Mol Pharm. 2018;16(1):71–85. Copyright 2018 American Chemical Society.165
Abbreviation: PEG, polyethylene glycol;

To overcome the drawbacks of PLGA hydrogels, such as
short blood circulation and quick uptake by the reticuloendothelial system (RES), PEG-MS and PL/PEG compositions
have been developed.162 These copolymers have largely
been utilized in medicine, notably, for CDDSs for proteins
and drugs. Their suitable interaction with drugs has alleviated
drug loading content (DLC) problems even though producing surface-modiﬁed PEG-MS and PL/PEG loaded with
drugs is a highly complicated issue because there are a few
surface attachments of PEG in the production of PLGA/
PEG.163,164 Jin et al developed sialic acid (SA) modiﬁed
lung-targeted microspheres (MS) conjugated with PLGA/
PEG (SA-PLGA/PEG-MS) to achieve the controlled release
of triphenylphosphonium cation (TPP) coated with Cur (CurTPP) for treating acute lung injury (ALI) through emulsion
solvent evaporation techniques. In vitro drug release studies
indicated that 63 and 20% TPP- Cur had a prolonged (72 h)
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and burst (3 h) release, respectively, from both SA-PEG-MS
and PL/PEG-MS and PLGA/PEG-MS. In another study, the
sustained cumulative release of a typical drug from a starchg-PEG/LA-based nanocarrier was investigated in typical
biological conditions showing highly-dependant behavior to
the structure of the polymer-based nanocarrier and also the
drug loading ability (Figure 9).165
Recently, Sánchez-López et al designed MemantinePEG-PLGA (MEM-PEG-PLGA) with the expectation of
targeting the blood-brain barrier (BBB) for Alzheimer’s
treatment. In this experiment, the MEM was well distributed in the matrix of PLGA. DLC results were promising
due to the growth of the thermogravimetric (Tg) parameter
of the polymeric solution, although there was not a clear
result concerning the strength of the interaction between
the drug and hydrogels. Both in vivo and in vitro studies
showed that the PLGA/PEG hydrogels delivered MEM in

submit your manuscript | www.dovepress.com

DovePress

4379

Maghsoudi et al

a controlled release manner to the target tissue, and the
improvement in the drug therapeutic effect demonstrated a
stable drug amount into the target organ.166
Likewise, in vitro, DOX release was controlled when
loaded with a high afﬁnity single-stranded EpCAM RNA
aptamer conjugated to PLGA-PEG copolymers. In favor
of PLGA-PEG nanopolymersomes, the cytotoxicity (P <
0.01) toward MCF-7 was greater than non-targeted nanopolymersomes, and the drug was released in a controlled
and sustained manner.167 Farajzadeh and colleagues conducted a study to evaluate the synergistic inhibitory effect
of Met and Cur loaded PLGA/PEG against T47D breast
cancer cells. The morphology and dynamic light scattering (DLS) results were utilized to improve the nanoformulations. The drugs were encapsulated into the PLGA/
PEG at a 1000:1 molar ratio, and the release proﬁle of
free drugs with the drug-NPs (Met-NP and Cur-NP) were
compared. Impressively, the drugs were released in a
sustained manner for more than 120 h without any initial
burst release. This combination not only killed the T47D
breast cancer cells more quickly than free drugs, but it
also decreased cytotoxicity and side effects to patients.168
Novel PEG-PLGA/PLGA nanoﬁbers were prepared and
then loaded with gentamycin through a solid-oil-in water
method to investigate the role of hydrogels in CDDSs. Drug
release kinetics from the polymeric nanoﬁbers were investigated by ﬁtting the drug release data within four kinetic
equations: zero order, ﬁrst order, Higuchi and KorsmeyerPeppas models. As a result, gentamycin content increased to
10.5 w/w% resulting in enhanced antibacterial activity as
well as complete sustained release after 10 h.169 The anticancer activity of 9-cis-retinoic acid incorporated PEGcoated PLGA NPs was reported by Cosco et al. The
dynamic Franz-type diffusion cell (comprised of a donor
and a receptor) separated by a cellulose acetate membrane
was evaluated for drug release. Therefore, the rapid and
prolonged release of 9-cis-retinoic acid after 10 h and 48 h,
respectively, were reported.170
It should be noted that blending has not always come
with sustained release. For instance, electrospun nanoﬁbers of PEGylated PLGA (PEG-PLGA) were selected to
evaluate the release kinetics of amoxicillin (AMX). When
recording the absorbance of the drug at 228 nm through a
Lambda 25 UV–vis spectrophotometer, the release proﬁles
of AMX from PLGA/AMX and PLGA-PEG/AMX nanoﬁbers were obtained. This study showed that PLGA-PEG
could release the drug in a faster manner than PLGA
nanoﬁbers. The reason is interesting: on account of the
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hydrophilicity of both AMX and PEG, and on the other
hand, the hydrophobicity of PLGA in that its hydrophilicity was improved by PEG, AMX is more likely to disperse uniformly in the PLGA-PEG/AMX nanoﬁbers than
in the PLGA/AMX nanoﬁbers. The greater surface area of
the nanoﬁbers also played a critical role. Furthermore, 3%
PLGA/AMX exhibited a smaller release of AMX than 5%
AMX/PLGA ﬁbers (2 days) while the release proﬁle for
AMX for 3% PLGA-PEG/AMX was higher than for 5%
PLGA-PEG/AMX nanoﬁbers because of the low quantity
of incorporation which was dispersed much more uniformly in the 3% PLGA-PEG/AMX than in the 5%
PLGA-PEG/AMX nanoﬁbers.171 In Table 4, additional
applications of PLGA blends are summarized for the controlled release of various drugs.

Applications of PLA Blends in CDDSs
Undoubtedly, PLA— as a tremendously versatile and aliphatic polyester discovered by Carothers in 1932172—is a biopolymer with much potential for biomedical applications. It
can be produced by lactic acid (obtained by the fermentation
of sugars originating from renewable resources) polymerization or through the ROP of lactic acid. Therefore, it is astonishingly biocompatible, biodegradable, eco-friendly and
sustainable.173,174 PLA, additionally, has been extensively
used in producing tissue scaffolds and drug carriers because
of its degradability in carbon dioxide and water in vivo.175
PLA possesses three stereoisomers: semi-crystallized poly
(D-lactide acid) (PDLA), poly(L-lactide acid) (PLLA) and
amorphous poly(DL-lactide acid) (PDLLA), each with different structures as carriers for drug delivery.176 During
recent years, various PLA blends have been introduced for
CDDSs as beneﬁcial copolymers for a wide range of medical
and pharmaceutical applications.173,177,178 In the last years,
many PEGylated PLA hydrogels have been synthesized and
investigated for their application in CDDSs.151 Sirc et al have
demonstrated the controlled release of some drugs based on
PLA/PEG hydrogels. They reported not only the sustained
release for Cyclosporine A (controlled release for a day)179
but more recently for PTX. The compositions of PLA/PEGPTX were architected by a needleless electrospinning technique. HPLC-UV analysis ensured the advantages of this
hydrogel on the prolonged and efﬁcient release of PTX,
including the sustained release of PTX in favor of additional
ratios of PEG (15 wt %), remarkable cytotoxicity of PLA/
PEG-PTX ﬁbers against a human ﬁbrosarcoma HT1080 cell
line, as well as an increased antiangiogenic effect.
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Table 4 Other Applications of PLGA-Based Hydrogels in CDDSs
Loaded Active

Blend Composition

Component

Duration of Release

Therapeutic Effect

Ref.

(Days)

TCH

PLGA/Gum tragacanth

75

Potential for periodontal diseases

172

Neuregulin-1

PLGA/NCO-sP(EO-stat-PO)

7

Potential for myocardial ischemic

173

Caffeine

PLGA/PLA

30

Suitable for sustained drug release

174

Cur

PLGA/Poloxamer

4

Protecting the drug from rapid CURC hydrolytic

175

degradation
Teriparatide

PLGA/PHBV

50

Enhance serum calcium concentration

176

Ibuprofen

PLGA/PCL

17

Effective for drug encapsulation & sustained release

177

Fenbufen

PLGA/CS

1

Treatment of acute & chronic pain

178

SDF-1α

PLGA/PEG-PLGA

3

Trapping of glioblastoma cells

179

Amphotericin B

PLGA/PLGA-PEG

7

Potential for antifungal therapy

180

Naringin

PLGA/PLLA/PDLLA

20

Potential for bone regeneration therapy

181

Triamcinolone acetonide

PLGA/mPEG

45

Treatment of chronic & recurrent uveitis

182

Vancomycin, gentamicin, and

PLGA/Collagen

14

Wound healing

183

Tenofovir

PLGA/PCL

10

Potential as drug carriers and sustained release

184

Sorafenib and DOX

PLGA/PEG

6&1

Improved cellular uptake in cancer cells

185

Cathelicidin-BF (BF30)

PLGA/4-arm-PEG

15

Enhanced antibacterial therapy

186

Cur

PLGA/PEG-B6

3

Potential for Alzheimer’s disease

187

Bevacizumab

PLGA/PCADK

50

Potential for ocular diseases

188

Simvastatin

PLGA/PEG

3

Treatment of osteoporosis

189

DOX

PLGA/PEG

5

Potential for cancer treatment

190

Rutin and Benzamide

PLGA/PEG

5

Potential for anti-bioﬁlm therapy

191

5-FU

PEG/PLGA-PCL

3

Induces apoptosis in HT-29 human colon cancer cells

192

Insulin

PPP/CS

60

Potential for subconjunctival injection & ocular drug

193

Dactolisib

PLGA/PEG

10

Potential for anti-inﬂammatory therapy

194

Acyclovir

PLGA/PEG

18

Potential as drug carriers and sustained release

195

lidocaine

delivery

Abbreviations: CURC, The pharmacological potential of curcumin; SDF-1α, stromal cell-derived factor-1 alpha; PPP, PLGA-PEG-PLGA triblock; FDZ, furazolidone; CS,
chitosan; PEG, polyethylene glycol; ASCs, adipose-derived stem cells; Bfgf, basic ﬁbroblast growth factor; HA, hyaluronic acid; TCH, tetracycline hydrochloride; BMP-2, bone
morphogenetic protein-2; BSA, bovine serum albumin; PAM, polyacrylamide; SA, sodium alginate; PVA, polyvinyl alcohol; SA, salicylic acid; CDDS, controlled drug delivery
system; PVP, polyvinyl propyl; HPMS, hydroxyl-terminated polydimethylsiloxane; PCL, polycaprolactone; NCO-SP, star shaped polyethylene oxide based prepolymers; DOX,
doxorubicin; EO, electro-optic; PO, polyoleﬁn; 5-FU, 5-ﬂuorouracil.

Most signiﬁcantly, an in vivo study illustrated that PTX (at
a concentration of PTX 0.1mg/cm2) loaded PLA-PEG(20)
(PLA-PTX(10)-PEG(20)) prevented tumor recurrence, which
paved the way for beneﬁcial and safe local recurrence of tumor
treatment.180 PEG-b-PLA NPs were designed through an
organocatalyzed ring-opening polymerization process for
assessing the in vitro drug release kinetics of Rhodamine B
base (RhB), by utilizing two various surfactants to achieve
diversely charged NPs: (i) choline chloride (CC) for positive
charges and (ii) sodium dodecyl sulphate (SDS) for negative
charges. With respect to the previously synthesized hydrogel,
AC6, RhB loaded within AC6-NPs_SDS showed a prolonged
release time of over a day (Figure 10).181
The controlled release of an important cephalosporin
antibiotic drug, ceﬁxime (Cfx), was assessed by Sherif et al
who developed an effective composition prepared from PLA/
PCL blends, including nano-hydroxyapatite (n-HA)—a
prime mineral material of bone tissue in mammals—loaded
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with β-cyclodextrin (β-CD) and Cfx (PLA/PCL-βCD-Cfx) in
the electrospun membranes. To evaluate the controlled
release proﬁle, PLA/PCL-nHA membranes were placed
into 30 mL of a PBS solution. In the presence of βCD, the
release of the drug was controlled to about half after 24 h,
which exhibited a promising delivery approach of Cfx over a
proper time period.182 Correspondingly, the Herrero group
reported effective controlled BSA release from electrospun
membranes of PLA/PCL blends possessing micron ﬁber
diameters. Electrospinning parameters—such as ﬂow rate,
voltage, distance to the collector and solvents—played a
crucial role in determining drug loading and release. As a
consequence, PLA/PCL was able to cumulatively release
BSA for up to three weeks.172 This study also highlights
the additional signiﬁcant improvement that could be obtained
through the use of nanometer ﬁbers, rather than the aforementioned studied micron ﬁbers, due to their signiﬁcantly
greater surface area.
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Figure 10 (A) Preparation of the drug loaded carrier and (B) the sustained release of RhB in AC6-NPs. Reproduced from Mauri E, Negri A, Rebellato E, Masi M, Perale G,
Rossi F. Hydrogel-nanoparticles composite system for controlled drug delivery. Gels. 2018;4(3):74. Creative Commons license and disclaimer available from: http://
creativecommons.org/licenses/by/4.0/legalcode.181
Abbreviations: DCM, dichloromethane; NPs, nanoparticles; SDS, sodium dodecyl sulfate.

Several publications have reported the promising beneﬁts
of biodegradable copolymer use for CDDSs of pesticides and
fertilizers, such as reducing environmental hazards, improving
agricultural product yields, decreasing environmental contamination and reducing phytotoxicity.183–186 Under these advantages, Wang et al reported CDDSs for pesticides,
azoxystrobin, and difenoconazole, by exploiting the solvent
evaporation method to obtain low toxicity and synergetic
effects by utilizing microsphere poly (butylene succinate)
(PBS) blended with PLA (70/30 w/w) as shells. Compared
to the difenoconazole-ascomycete (5:8) 32.5% w/v suspension
concentrate (SC) with 17 days of release, it was the PLA/PBS
microsphere which helped the cumulative release of the drugs
for up to 25 days at a concentration ratio of about 85%.187
Numerous studies have researched the advantages of
PLA/PLGA copolymers, including their biodegradability
and mechanical properties as well as their effective role in
CDDSs of opioid antagonists, anti-cancer, anti-diarrheal,
anti-bacterial, anti-psychotic, anti-inﬂammatory and anti-diabetic drugs for intramuscular, subcutaneous, periodontal and
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oral administration.188–192 Milovanovic et al used a PLA/
PLGA matrix with supercritical carbon dioxide (scCO2) as
an effective solvent to proceed with the production of PLA/
PLGA foams for the controlled delivery of thymol (a model
drug) in a single-step procedure according to supercritical
impregnation and foaming. The tested foams could release
thymol in a controlled manner based on DSC and FTIR
analyses between 3 to 6 weeks in PBS at 37 °C.
Furthermore, the maximum thymol release rate (6.62%) of
this foam demonstrated controlled release of the drug (3
days) at a pH value of 1.1.193 Hence, high surface area,
tunable pore size and pore interconnectivity of pores could
lead to remarkable controlled release carriers.
PLA would be an excellent candidate for polymer blending for a diverse number of medical applications. However,
the commercial use of PLA blends has been restricted and is
a long way from scale-up to date. Stable and effective formulations of PLA blends need to be more of a focus. In
Table 5, additional applications of PLA-based NPs are summarized for the controlled release of various drugs.
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Table 5 Other Applications of PLA-Based Hydrogels in CDDSs
Loaded Active

Blend Composition

Component

Duration of

Therapeutic Effect

Ref.

Release (Days)

5-FU

PLA/PEG

>13

Improve drug pharmacokinetics & potential for solid tumors

194

TCH

PLA/PCL

10

Wound healing and quick surgery infective protection

195

Methylene Blue
Minocycline

PLA/PEG
PLA/PEG

120
12

Potential as drug carriers & sustained release
Treatment of periodontitis in dogs

196

Cur

PLA/HPG

3

Wound dressing

198

Teriﬂunomide
Anastrozole

PLA/PBAd
PLA/PEG-PLA

>5
6

Treatment of rheumatoid arthritis
Treatment of breast cancer cell lines

199

Naltrexone
Risperidone

PLA/PVA
PLA/PPAd

>30
6

Conventional treatment of medical conditions and sustained release
Increase the short-term drug activity

201

Salicylic acid

PLA/CS

5

Potential as drug carriers & sustained release

177

Voriconazole
DOX

PLA/PESu
PLA/PVP

>3
6

Treatment of skin infection
Improve drug loading efﬁciency and incorporation

203

Cfx

PLA/PEG

>1

Potential as drug carriers & sustained release

24

Celecoxib

PLA/PEtG

1

Potential for anticancer therapy

205

197

200

202

204

Abbreviations: PBAd, poly(butylene adipate); HPG, hyperbranched polyglycerol; PPAd, poly(propylene adipate); PESu, poly(ethylene succinate); PEtG, poly(ethylglyoxylate)
CS, Chitosan; PEG, polyethylene glycol; PAM, polyacrylamide; PVA, polyvinyl alcohol; CDDS, controlled drug delivery system; PVP, polyvinyl propyl; DOX, doxorubicin; PLA,
Polylactic acid; Cfx, Ciproﬂoxacin; 5-FU, 5-Fluorouracil; PCL, polycaprolactone; TCH, Tetracycline hydrochloride; Cur, curcumin.

Applications of PGA Blends for CDDSs
PGA is a safe and non-immunogenic polymer that was
initially explored for the delivery of small products and
antitumor agents in Phase III trials. PGA nanoparticles
have been widely used as polymer-carriers for CDDSs due
to their superb biodegradability and biocompatibility properties, which are being utilized for the targeted delivery of
poorly soluble or unstable bioactive compounds bringing
about low side effects and high drug loading efﬁcacy.194–196
Nevertheless, PGA has some limitations in CDDSs, such as
insolubility in common solvents, problems in fabrication,
high melting temperature (220 °C) and high crystallinity of
approximately 50%.197,198
Accordingly, a naturally occurring anionic polypeptide
γ-PGA—linked by the peptide bond among the α-amino
and the abundant γ-carboxyl groups30—produced mostly
using Bacillus subtilis bacteria199, has gained popularity
on account of its satisfactory water solubility, favorable
ﬁber-formation, ﬁlm-forming ability, plasticity, and most
greatly, for its activity in controlled drug release.175
Notably, γ-PGA with a negatively charged structure can
blend with a positively charged polymer, providing electrostatic interactions to make biocompatible and biodegradable compositions, see Figure 11.200
Novel injectable and stimuli-responsive γ-PGA/collagen hydrogels loaded with DOX and granulocyte-macrophage colony-stimulating factor (GM-CSF) were

International Journal of Nanomedicine 2020:15

developed by Cho et al. The γ-PGA ameliorated the innate
temperature-based phase transition nature of collagen to a
limited viscous sol and non-ﬂowing gel states at room and
body temperatures, respectively.
Chung et al exploited a spin-coating technique for the
controlled release of bone morphogenetic protein 2 (BMP2) incorporated with polyelectrolyte multilayers of CS/γPGA coated on a Ti6Al4V substrate. To fully decompose
ex vivo, the prepared ﬁlm required a 5–8 µm thickness and
more than 45 days. Consequently, a 50% release of BMP-2
was observed to have an initial burst release within 3 h,
while after that, the controlled release of BMP-2 over a
span of 5 days was reported.202
In a recent study, aldehyde hyaluronic acid (HA-CHO)
hydrazide-modiﬁed γ-PGA (γ-PGA-ADH) was synthesized
to form HA/γ-PGA hydrogels through a Shiff base reaction.
The controlled release of BSA as a biological compound with
a variety of composition ratios was conﬁrmed after 30 h
during either diffusion or case-II relaxation mechanisms.203
Temperature and pH-responsive hydrogels based on poly
(NIPAAm-co-poly (γ-glutamic acid) - Allyl glycidyl ether)
(poly (NIPAAm-co- γ-PGA -AGE)) were synthesized by
crosslinking polymerization to evaluate the controlled
release of naproxen. In this study, γ-PGA-Allyl glycidyl
ether (γ-PGA-AGE), which was obtained by the reaction of
γ-PGA and AGE through ring-opening grafting, played an
indispensable role in preparing the thermo/pH-sensitive
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Figure 11 The composition between γ-PGA as the negatively charged polymer and the positively charged polymer CS. Reproduced from Khalil I, Burns A, Radecka I, et al.
Bacterial-derived polymer poly-y-glutamic acid (y-PGA)-based micro/nanoparticles as a delivery system for antimicrobials and other biomedical applications. Int J Mol Sci.
2017;18(2):313. Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode.200
Abbreviation: γ-PGA, poly-γ-glutamic acid.

NIPAAm-co- γ-PGA -AGE hydrogels. The cytocompatibility of the hydrogels was enhanced by increasing the ratio of
γ-PGA-AGE. After 36 h, naproxen was released at 88 and
81% according to r= 0.20 and r= 0.15 hydrogels, respectively, while for r= 0.05 and r= 0.10, up to 12 h was required
to reach the maximum release rate. As a result, the poly
(NIPAAm-co-γ-PGA-AGE) hydrogels can be considered as
a controlled drug release carrier.30
A novel diblock copolymer d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(e-caprolactone-ran-glycolide) (TPGSb-(PCL-ran-PGA) (TPP) was synthesized
by ring-opening polymerization incorporated with potential antifungal drug itraconazole (ITZ) to form ITZ-TPP
NPs by a modiﬁed double emulsion technique. Not only
did this composition enhance antifungal activity of ITZ
with no clear cytotoxicity on HeLa cells and ﬁbroblasts
nor any obvious inhibitory activity against fungal growth,
more importantly, it showed a controlled release from
23.75 and 56% of the encapsulated drug during the ﬁrst
3 days and more than 12 days, respectively.197 Liu et al
developed polymersomes of folic acid (FA), which were
effective for the controlled and targeted release of DOX,
and the diblock PGA/PCL (FA-PGA-b-PCL) for
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ultrasensitive transverse (T2) MRI. Afterward, ultra-small
superparamagnetic iron oxide NPs (SPIONs) were
explored in situ as hydrophilic PGA coronas of FA-PGAb-PCL to obtain magnetic polymersomes. Thus, a lower
water diffusion coefﬁcient and higher fruitful diameter
were achieved, which could be a potential advantage
resulting in greater T2 relaxivity of the FA-PGA-b-PCL.
Besides, in terms of controlled release, DOX loaded FAPGA-b-PCL released in a controlled manner for about 15
days. Both in vitro and in vivo tests reported that DOX
was delivered and released signiﬁcantly into the nucleus of
HeLa cells with great efﬁciency (ie, tumor volume
decreased gradually after two weeks) owing to the certain
recognition and binding between FA on the surface of the
polymersomes and the FA receptors on cancer cell
membranes, indicating that these DOX-loaded magnetic
polymersomes are favorable for numerous biomedical
applications.204
Many studies have highlighted the different strategies of
modern drug delivery to overcome the serious dilemma of
platinum (II) drugs for cancer therapy, such as drug resistance, detoxiﬁcation and side effects.205–208 Recently, Yang
et al developed a novel micelle of methoxy PEG-PGA and
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Figure 12 Schematic illustration of the preparation of a typical polymer nano blend system.

newly synthesized cisplatin derivative PyPt M (PyPt) as
PyPt drugs in the polymeric core and PEG as the shell.
PyPt is a poorly water-soluble drug, however, its aquated
species can interact with mPEG-b-PLG—with the protection of PyPt from glutathione (GSH) detoxiﬁcation—to
enhance solubility in order to increase cellular uptake and
the cytotoxicity of M (PyPt) compared to free cisplatin and
PyPt. Consequently, the beneﬁts of M (PyPt) include less
detoxiﬁcation of GSH in PyPt, resulting in a high afﬁnity to
bind DNA, higher apoptosis, improved cisplatin efﬁcacy
and resistance. Moreover, the M (PyPt) demonstrated the
potential controlled release of Pt in tumor micro-environments, which prohibited the division of cancer cells.
However, basically, the preparation of a nano polymer
blend system is the same for any study and investigation,
and follows basic rules in this matter (Figure 12).209
The controlled release necessary for overcoming biological barriers related to the oral administration of peptides was reported by Niu and co-workers. In this scenario,
they created core-shell nanoparticles in which the core was
a hydrophobically-modiﬁed cell-penetrating peptide (CPP)
and insulin and the shell was a selected model peptide
along with the copolymer PGA-PEG in order to preserve
the drug and carrier from the inclement conditions of the
intestine. Moreover, they chose octaarginine (r8) as the
CPP, which can interact with insulin through electrostatic
and hydrophobic forces. One way to design PGA-PEG
enveloped r8-insulin nano-complexes (ENCPs) is to dissolve PGA-PEG in water, followed by evaporating water
in a round ﬂask under reduced pressure at 37 °C, then
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adding r8-insulin nano-complexes (NCPs) to the ﬂask for
about a 10 min rotation until the NCPs were enveloped
with the ﬁlm, followed by the adjustment of ENCPs at a
pH of 7. ENCPs had such fascinating advantages, such as
the potential controlled release of insulin in vivo
(release from the ENCPs was slower than the NCPs
alone), better protection of insulin from enzymatic degradation and to solidify in simulated intestinal ﬂuid (SIF).210

Conclusions and Future Prospects
This review scrutinized recent developments and the characterization of nano polymeric blends for CDDSs.
Recently, CDDSs have attracted much attention due to
their massive advantages over conventional drug therapy.
They are distinguished by a variety of categories, such as
diffusion-controlled, chemically controlled, solvent activated and modulated release systems.50 CDDSs have
been additionally reported in which drugs can be dissolved
or dispersed in the ﬁlms. The effective delivery of a drug
at a controlled rate over an accurate time frame to a
selected target organ has been the absolute necessity in
drug delivery technology and pharmacokinetics.
Polymer blends have demonstrated a good response to
external stimuli—such as pH, temperature, ionic factor, electric ﬁeld and magnetic ﬁeld—which can be regarded as a
novel class of carriers or coating materials for sustained drug
release and for CDDSs. Synthetic as well as naturally occurring polymers can blend to generate a hybrid polymer with
new physical and chemical properties. Examples of naturally
occurring polymers include CS, cellulose, and starch, while
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on the other hand, PLGA, PLA and PGA are salient examples of synthetic polymers.
Different types of drugs can be fabricated into biocompatible and biodegradable polymers with various strategies. During past years, there has been a promising need
for the development of polymer blends, and these necessities will continue to steadily increase in the future.
Moreover, polymer blends loaded with a drug could
release a drug over a prolonged time by reducing the
drug dosage and unwanted toxic effects. Consequently,
these compositions are ideal candidates for CDDSs.
However, functionality and drug release mechanisms of
these systems are highly complicated, more than that of
just one polymer. Thus, it is worth implementing a practical decision to reduce time and a cost-intensive series of
trial and error experiments in order to accurately assess
therapeutic efﬁcacy and ameliorate the clinical practice of
polymer blends. It is of critical importance to evaluate
such systems more clinically and pathologically in animal
models.
Therefore, in summary, even though improvements and
enhancements have been reported by numerous researchers worldwide, there are still too many challenges that
must be solved before the widespread use of nano polymer
blends are realized in medicine. In addition, the ﬁeld of
CDDSs suggests a large variety in scope and prospect to
develop novel technologies with high performance and
potential economically viable solutions, issues commonly
ignored in today’s published papers.
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